Cagrilintide: what the literature says about this long-acting amylin analog
An acylated, stabilized analog of human amylin, cagrilintide is studied for its non-selective activation of AMY receptors and its half-life compatible with weekly protocols.
Cagrilintide is an acylated, stabilized analog of human amylin, a peptide hormone co-secreted with insulin by pancreatic β-cells. Its design illustrates a now-classic chemical strategy: extending the lifespan of a native peptide without altering its target.
Acylation designed for duration
The sequence carries a C20 diacid chain that allows reversible binding to plasma albumin (PMID 34043941). This circulating reservoir slows renal elimination and considerably extends exposure. The literature reports a half-life on the order of 159 to 195 hours, compatible with the weekly protocols described in the studies.
Non-selective activation of AMY receptors
Amylin has no receptor of its own: it acts on complexes formed by the calcitonin receptor (CTR) associated with the RAMP1, RAMP2, or RAMP3 proteins, forming the AMY1R, AMY2R, and AMY3R receptors, respectively. Studies describe non-selective activation of all three complexes by cagrilintide, with Gαs coupling, cAMP production, and slow receptor dissociation — a molecular correlate of the observed duration of action.
Central circuits described
At the brainstem level, the literature (PMC9542837) reports activation of neurons in the area postrema and the nucleus tractus solitarius, structures located outside the blood-brain barrier. Downstream, studies describe modulation of hypothalamic POMC/CART populations, slowed gastric emptying, and suppression of postprandial glucagon secretion in the models studied.
Mechanistic complementarity with the incretin pathway
Academic interest in cagrilintide largely stems from its mechanistic distinction from GLP-1 agonists: the amylin pathway and the incretin pathway converge on comparable effects through different receptors. Co-administration protocols are explored in the literature (PMID 37364590), precisely because the two pathways do not overlap.